Featured Research

from universities, journals, and other organizations

Reversing resistance to sunitinib: Findings may help patients with deadly kidney cancer

Date:
February 19, 2010
Source:
Van Andel Research Institute
Summary:
Researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma, a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

Kidney cancer is among the 10 most common cancers in both men and women, striking nearly 50,000 Americans in 2009 and killing more than 11,000. Renal cell carcinoma (RCC) accounts for 9 out of 10 kidney cancers, and ccRCC is the most common subtype, accounting for 8 out of 10 RCC cases.

"The research from Dr. Teh's (VARI) group is a critical step forward in understanding the mechanisms of response and resistance to the new standard of care therapies in renal cell carcinoma such as sunitinib," said Brian Rini, MD, Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute.

Sunitinib received FDA approval in 2006 and is a standard of care for both ccRCC and gastrointestinal stromal tumors. The drug is being investigated as a possible therapy for other cancers, including breast cancer, colorectal cancer, and non-small cell lung cancer.

Researchers found that ccRCC tumor cells that had developed a resistance to sunitinib had increased secretion of the protein interleukin-8 (IL-8). Administering sunitinib and IL-8 neutralizing antibodies re-sensitized tumors to sunitinib treatment. Researchers also found that IL-8 may serve as a useful biomarker to predict patients' response to sunitinib treatment.

"The development of ccRCC resistance to sunitinib treatment is of major clinical concern," said VARI Distinguished Scientific Investigator Bin Tean Teh, M.D., Ph.D., whose laboratory published its findings in this month's issue of Cancer Research. "It is now of critical importance to validate these findings in the clinical setting."

Another study from Teh's laboratory also published in Cancer Research this month looked into exactly how sunitinib works. The study found that the treatment does not target tumor cells, but rather the tumor's blood supply.

"Understanding how sunitinib works should have important implications for the improved treatment of ccRCC and perhaps other cancers as well," said VARI Postdoctoral Fellow Dan Huang, Ph.D., lead author of both studies.

"These insights will help build upon recent advances to extend clinical benefits to more patients with metastatic kidney cancer," said Dr. Rini.

(Disclosure: Dr. Rini is a paid consultant of and has a research funding relationship with Pfizer, Inc., which partially funded this study).


Story Source:

The above story is based on materials provided by Van Andel Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

Van Andel Research Institute. "Reversing resistance to sunitinib: Findings may help patients with deadly kidney cancer." ScienceDaily. ScienceDaily, 19 February 2010. <www.sciencedaily.com/releases/2010/02/100218110936.htm>.
Van Andel Research Institute. (2010, February 19). Reversing resistance to sunitinib: Findings may help patients with deadly kidney cancer. ScienceDaily. Retrieved April 25, 2014 from www.sciencedaily.com/releases/2010/02/100218110936.htm
Van Andel Research Institute. "Reversing resistance to sunitinib: Findings may help patients with deadly kidney cancer." ScienceDaily. www.sciencedaily.com/releases/2010/02/100218110936.htm (accessed April 25, 2014).

Share This



More Health & Medicine News

Friday, April 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins